<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Article Tag Suite 1.1//EN"
  "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink"
         xmlns:mml="http://www.w3.org/1998/Math/MathML"
         article-type="research-article"
         xml:lang="en">
  <front>
    <journal-meta>
      <journal-title-group>
        <journal-title>American Journal of PharmTech Research</journal-title>
        <abbrev-journal-title abbrev-type="publisher">AJPTR</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="epub">2249-3387</issn>
      <publisher>
        <publisher-name>undefined</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">AJPTR35034</article-id>
      <title-group>
        <article-title>Formulation and Evaluation of Labetalol Hydrochloride Fast Dissolving Tablets</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Hilal</surname>
            <given-names>Mohd Mirasuddin</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hussain</surname>
            <given-names>Md. Mumtaz</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Shreen</surname>
            <given-names>Sara</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Parveen</surname>
            <given-names>Saba</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Reddy</surname>
            <given-names>R. Balaji</given-names>
          </name>
        </contrib>
      </contrib-group>
      <pub-date pub-type="epub" iso-8601-date="2013-10-01">
        <month>10</month>
        <day>01</day>
        <year>2013</year>
      </pub-date>
      <volume>3</volume>
      <issue>5</issue>
      <abstract>
        <p>The purpose of this research was to develop fast dissolving tablets of labetalol hydrochlorideis a phenyl ethanol amine derivative that is a competitive inhibitor at both β1 and β2 adrenergic receptors and at the α1-adrenergic receptor. Labetalol is an antihypertensive drug and the dose is 50-200mg twice/day with food. From the present study, the drug content was uniform in all the labetalol FDT formulations prepared. The drug and super disintegrating agent ratio was found to influence the release of drug from the formulations. As the level of super disintegrating agent and disintegrant changed, the drug release rates were found to be increased in all formulations. The prepared tablets disintegrate within few seconds without need of water; thereby enhance the absorption leading to its increased bioavailability. Key words:  Labetalol, antihypertensive, super disintegrating agent, fast dissolving tablets.</p>
      </abstract>
      <kwd-group kwd-group-type="author">
        <kwd>Labetalol</kwd>
        <kwd>antihypertensive</kwd>
        <kwd>super disintegrating agent</kwd>
        <kwd>fast dissolving tablets.</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <!-- Full article body not available in metadata-only JATS export. See PDF/HTML galley. -->
  </body>
  <back/>
</article>
